GlassScriptPhysician profile
Paul D Deholl
NPI 1124029103
$40,670.72
in general payments reported to CMS, 2019-2025
9 companies · $8,700 in 2025
The $8,700 reported for 2025 was more than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
See the full distribution for Orthopaedic Surgery of the Spine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,915 · 2020: $2,799 · 2021: $5,778 · 2022: $5,521 · 2023: $4,986 · 2024: $8,973 · 2025: $8,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $22K · Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $21,861.49 |
| Food and Beverage | $796.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Degen Medical, INC. | $39,270.35 | 2019-2025 | Cyclops, E3, Cyclops |
| Medtronic, INC. | $615.29 | 2022-2025 | Mazor X System, Intellis Adaptivestim |
| Depuy Synthes Sales INC. | $206.07 | 2023-2025 | Velys, Expedium, Teligen |
| Globus Medical, INC. | $152.00 | 2022-2025 | Excelsius Gps |
| Orthofix Medical, INC. | $150.00 | 2023 | Trinity Elite |
| Medtronic USA, INC. | $140.16 | 2020 | |
| Cerapedics INC. | $98.99 | 2022 | |
| Nuvasive, INC. | $24.79 | 2020-2021 | |
| Stryker Corporation | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Deholl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.